43207-78-9

Usage

Synthesis Reference(s)

The Journal of Organic Chemistry, 33, p. 494, 1968 DOI: 10.1021/jo01266a004

InChI:InChI=1/C10H13NO/c1-12-10-3-2-8-4-5-11-7-9(8)6-10/h2-3,6,11H,4-5,7H2,1H3

Upstream product

• 39989-39-4 7-methoxyisoquinoline 
• 22246-04-4 7-methoxy-3,4-dihydro-2H-isoquinolin-1-one 
• 64-17-5 ethanol 
• 221656-41-3 2-(1H-1,2,3-benzotriazol-1-ylmethyl)-7-methoxy-1,2,3,4-tetrahydroisoquinoline 
• 136390-01-7 ethyl-N-<2-(4-methoxyphenyl)ethyl>-carbamate 
• 1348500-58-2 C₁₀H₁₃NO 
• 215453-91-1 tert-butyl 7-methoxy-3,4-dihydroisoquinoline-2(1H)-carboxylate 
• 101033-24-3 4-methoxycinnamyl isocyanate 
• 34446-64-5 (E)-3-(4-methoxyphenyl)propenoyl chloride 
• 943-89-5 (E)-3-(4-methoxyphenyl)acrylic acid 
• 16027-16-0 7-methoxy-2H-isoquinolin-1-one 
• 111874-91-0 C-(3,4-Dichloro-phenyl)-N-[2-(4-methoxy-phenyl)-ethyl]-methanesulfonamide 
• 591-31-1 3-methoxy-benzaldehyde 
• 39964-84-6 (3-Methoxy-benzylidenamino)-acetaldehyd-dimethylacetal 

Downstream Products

• 1745-13-7 7-methoxy-1,2,3,4-tetrahydro-isoquinoline; picrate 
• 110192-19-3 7-hydroxy-1,2,3,4-tetrahydroisoquinoline hydrobromide 
• 508235-80-1 5-(3,4-Dimethoxybenzylamino)-2-(2-furyl)-8-(7-methoxy-1,2,3,4-tetrahydroisoquinolin-2-ylmethyl)[1,2,4]triazolo[1,5-c]pyrimidine 
• 215453-91-1 tert-butyl 7-methoxy-3,4-dihydroisoquinoline-2(1H)-carboxylate 
• 54893-23-1 7-methoxy-N-methyl-1,2,3,4-tetrahydroisoquinoline 
• 1187947-97-2 1-[2-methyl-7-(2-morpholin-4-yl-ethoxy)-1,2,3,4-tetrahydro-isoquinolin-4-yl]-cyclohexanol 
• 88493-58-7 1,2,3,4-tetrahydro-2-methylisoquinolin-7-ol 
• 1373622-11-7 6-iodo-4-(7-methoxy-3,4-dihydro-1H-isoquinolin-2-yl)-quinazoline 
• 1394241-71-4 C₁₇H₁₇NO₅S 
• 1390656-08-2 7-(2,6-dichlorobenzyl)-5-[(7-methoxy-1,2,3,4-tetrahydroisoquinolin-6-yl)amino]pyrido[3,4-d]pyridazin-4(3H)-one 
• 1390657-71-2 tert-butyl 6-(7-(2,6-dichlorobenzyl)-4-oxo-3,4-dihydropyrido[3,4-d]pyridazin-5-ylamino)-7-methoxy-3,4-dihydroisoquinoline-2(1H)-carboxylate 

Relevant academic research and scientific papers

Intramolecular Reductive Cyclization of o-Nitroarenes via Biradical Recombination

A visible-light-induced/thiourea-mediated intramolecular cyclization of o-nitroarenes under mild conditions is realized for the first time, which provides an efficient and environmentally friendly way to access pharmaceutical relevant quinazolinone derivatives. The reaction can be easily extended to gram level by using a continuous-flow setup with high efficiency. Mechanistic investigation including control experiments, transient fluorescence, UV-vis spectra, and DFT calculations suggests that the formation of active biradical intermediates via intramolecular single electron transfer (SET) is key stage in the catalytic cycle.

Light-Driven Intramolecular C?N Cross-Coupling via a Long-Lived Photoactive Photoisomer Complex

Reported herein is a visible-light-driven intramolecular C?N cross-coupling reaction under mild reaction conditions (metal- and photocatalyst-free, at room temperature) via a long-lived photoactive photoisomer complex. This strategy was used to rapidly prepare the N-substituted polycyclic quinazolinone derivatives with a broad substrate scope (>50 examples) and further exploited to synthesize the natural products tryptanthrin, rutaecarpine, and their analogues. The success of gram-scale synthesis and solar-driven transformation, as well as promising tumor-suppressing biological activity, proves the potential of this strategy for practical applications. Mechanistic investigations, including control experiments, DFT calculations, UV-vis spectroscopy, EPR, and X-ray single-crystal structure of the key intermediate, provides insight into the mechanism.

UREA PEPTOID BORIC ACID COMPOUND, PHARMACEUTICAL COMPOSITION THEREOF, PREPARATION METHOD THEREFOR, AND USES THEREOF

The present invention provides a urea peptidomimetic boronic compound and pharmaceutical compositions thereof, their preparative methods and uses. The compounds are represented by the following formula (I).

Tyrosine Kinase Inhibitor And Uses Thereof

Disclosed is a compound of Formula (I) or a pharmaceutically acceptable salt, ester, or solvate thereof, or their stereoisomers, which can be used as tyrosine kinase inhibitor. Also disclosed is a method for preparing the compound, a pharmaceutical composition and a kit comprising the compound, and uses of the compound. The compound can be used as tyrosine kinase inhibitor, or can be used to reduce or inhibit activity of EGFR or mutant thereof, such as EGFR mutant comprising T790M mutation, in a cell, or to treat and/or prevent a disease associated with overactivity of EGFR, such as cancer.

Synthesis and in vitro evaluation of tetrahydroisoquinolines with pendent aromatics as sigma-2 (σ2) selective ligands

5-Bromo-N-[4-(6,7-dimethoxy-3,4-dihydro-1H-isoquinolin-2-yl)-butyl)]-2, 3-dimethoxybenzamide 1 is a potent and selective σ2 receptor ligand suitable for further development. A series of new analogues, incorporating a variety of isoquinoline and carboxylic acid moieties, linked together with either a linear or cyclic amine spacer have been synthesised and assessed for their σ1/σ2 binding affinity and selectivity. Compounds with a rigid piperidine spacer gave Ki values for the σ2 receptor between 8.7-845 nM. Changing the configuration of the methoxy groups on the isoquinoline moiety resulted in molecules with σ2Ki values of 4.4-133 nM whereas varying the length and flexibility of the carbon spaces gave σ2Ki values 0.88-15.0 nM, some of the most active, selective σ2 ligands to date. Thus, the flexibility and length of the carbon linker and the carboxylic acid moiety are confirmed to be key to the exceptional binding affinity and selectivity for this active series. Additionally, the incorporation of a halogen on selected carboxylic acid moieties provided a convenient strategy for the introduction of a radiohalogen for applications in pharmacological and imaging studies.

BICYCLIC INHIBITORS OF ALK

The present invention relates to compounds of formula (1) or pharmaceutical acceptable salts, wherein R1, X, Y, Z, A, B, G1, and n are defined in the description. The present invention relates also to compositions containing said compounds which are useful for inhibiting kinases such as ALK and methods of treating diseases such as cancer.

NOVEL MONOAMINE RE-UPTAKE INHIBITOR

The present invention relates to novel compounds of Formula (I), their pharmaceutically acceptable derivatives, tautomeric forms, stereoisomers including R and S isomers, polymorphs, prodrugs, metabolites, salts or solvates thereof. The invention also rel

SAR studies of capsazepinoid bronchodilators. Part 1: The importance of the catechol moiety and aspects of the B-ring structure

Capsazepine as well as its derivatives and analogues are general inhibitors of constriction of human small airways. From a systematic variation of the capsazepine structure, divided into four regions, SARs were established. This part concerns the catechol moiety of the A-ring as well as the 2,3,4,5-tetrahydro-1H-2-azepine moiety (the B-ring) of capsazepine. It is revealed that a conformational constrain (as a fused ring) is important and that compounds with a six-membered B-ring (as a 1,2,3,4-tetrahydroisoquinoline) in general are more potent than the corresponding isoindoline, 2,3,4,5-tetrahydro-1H-2-benzazepine and 2,3,4,5-tetrahydro-1H-3-benzazepine derivatives.

Synthesis and in vitro opioid receptor functional antagonism of analogues of the selective kappa opioid receptor antagonist (3R)-7-hydroxy-N-((1S)-1- {[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl}-2-methylpropyl) -1,2,3,4-tetrahydro-3-is

In previous structure-activity relationship (SAR) studies, we identified (3R)-7-hydroxy-N-((1S)-1-{[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1- piperidinyl]methyl}-2-methylpropyl)-1,2,3,4-tetrahydro-3- isoquinolinecarboxamide (JDTic, 1) as the first poten

AZACYCLIC COMPOUNDS AS INHIBITORS OF SENSORY NEURONE SPECIFIC CHANNELS

Compounds of the formula (I), and pharmaceutically acceptable salts thereof, are found to be antagonists of SNS sodium channels. They are therefore useful as analgesic and neuroprotective agents wherein: X is -N- or -CH-; n is from 0 to 3.